← Leaderboards
Marina Caskey
Rockefeller University
$39,777,285
Attributed
$55,509,477
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $15.1M · FY2009–25$20M$15M$10M$5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$66,191,756 · 9
By mechanism
UM1$30,481,566 · 2
U01$24,342,111 · 5
P01$10,682,279 · 1
K23$685,800 · 1
Top collaborators
- R. Brad Jones6 shared
- Michel C Nussenzweig3 shared
- Paul D Bieniasz2 shared
- Pamela J Bjorkman2 shared
- Theodora Hatziioannou2 shared
- Charles M. Rice2 shared
Most similar at Rockefeller University
Same institution · by research overlap
- Jeffrey Victor Ravetch$66,226,718
- Ralph M. Steinman$21,317,958
- Stylianos Bournazos$8,462,360
- Charles M. Rice$80,497,748
- Timothy Patrick Sheahan$10,595,033
Others in their field
Top investigators on “Immune Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,695,345
- Barton F Haynes · Duke University$456,664,915
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$309,708,725
- Peter B. Gilbert · Fred Hutchinson Cancer Center$192,329,665
Research focus
Immune ResponseVirusViralInfectionCellsNeutralizing AntibodyAntibodiesAntiretroviral TherapyHiv-1PreventResponseImmuneMediatingSuccessNonhuman PrimateViremiaImmune SystemIn VitroDoseSafetyAntigensClinical ResearchComorbidityT-Lymphocyte
Grant awards (33)
REACH: Research Enterprise to Advance a Cure for HIV$5,432,259
UM1 · FY2025 · AI
INSPIRE: Innovative Strategies for Personalized Immunotherapies and Reservoir Eradication$2,948,452
UM1 · FY2025 · AI
Defining the mechanisms of HIV resistance to bNAbs in humans$1,569,774
U01 · FY2025 · AI · contact PI
First-in-human study of a potent anti-HBsAg neutralizing antibody$822,075
U01 · FY2025 · AI · contact PI
REACH: Research Enterprise to Advance a Cure for HIV$5,371,650
UM1 · FY2024 · AI
Defining the mechanisms of HIV resistance to bNAbs in humans$1,569,774
U01 · FY2024 · AI · contact PI
Immunologic control of HIV-1 through combination bNAbs and biologics.$1,437,689
U01 · FY2024 · AI · contact PI
First-in-human study of a potent anti-HBsAg neutralizing antibody$847,498
U01 · FY2024 · AI · contact PI
REACH: Research Enterprise to Advance a Cure for HIV$5,567,406
UM1 · FY2023 · AI
Broad neutralization of pandemic threat coronaviruses$4,259,011
P01 · FY2023 · AI
Immunologic control of HIV-1 through combination bNAbs and biologics.$1,596,752
U01 · FY2023 · AI · contact PI
Defining the mechanisms of HIV resistance to bNAbs in humans$1,569,774
U01 · FY2023 · AI · contact PI
First-in-human study of a potent anti-HBsAg neutralizing antibody$864,658
U01 · FY2023 · AI · contact PI
Broad neutralization of pandemic threat coronaviruses$6,423,268
P01 · FY2022 · AI
REACH: Research Enterprise to Advance a Cure for HIV$5,478,120
UM1 · FY2022 · AI
Immunologic control of HIV-1 through combination bNAbs and biologics.$1,667,616
U01 · FY2022 · AI · contact PI
Defining the mechanisms of HIV resistance to bNAbs in humans$1,569,774
U01 · FY2022 · AI · contact PI
REACH: Research Enterprise to Advance a Cure for HIV$5,683,679
UM1 · FY2021 · AI
3BNC117 and 10-1074 to suppress HIV-1 replication and reduce the reservoir$744,981
U01 · FY2021 · AI · contact PI
Immunologic control of HIV-1 through combination bNAbs and biologics.$2,161,658
U01 · FY2020 · AI · contact PI
3BNC117 and 10-1074 to suppress HIV-1 replication and reduce the reservoir$814,897
U01 · FY2020 · AI · contact PI
Immunologic control of HIV-1 through combination bNAbs and biologics.$1,678,283
U01 · FY2019 · AI · contact PI
3BNC117 and 10-1074 to suppress HIV-1 replication and reduce the reservoir$791,861
U01 · FY2019 · AI · contact PI
3BNC117 and 10-1074 to suppress HIV-1 replication and reduce the reservoir$846,953
U01 · FY2018 · AI · contact PI
3BNC117 and 10-1074 to suppress HIV-1 replication and reduce the reservoir$819,850
U01 · FY2017 · AI · contact PI
3BNC117 mAb in HIV-infected subjects on combination ART$697,741
U01 · FY2017 · AI · contact PI
3BNC117 mAb in HIV-infected subjects on combination ART$1,430,222
U01 · FY2016 · AI · contact PI
3BNC117 mAb in HIV-infected subjects on combination ART$840,281
U01 · FY2015 · AI · contact PI
Characterization of the immunity induced by a DEC205-targeted HIV vaccine$137,160
K23 · FY2013 · AI · contact PI
Characterization of the immunity induced by a DEC205-targeted HIV vaccine$137,160
K23 · FY2012 · AI · contact PI
Characterization of the immunity induced by a DEC205-targeted HIV vaccine$137,160
K23 · FY2011 · AI · contact PI
Characterization of the immunity induced by a DEC205-targeted HIV vaccine$137,160
K23 · FY2010 · AI · contact PI
Characterization of the immunity induced by a DEC205-targeted HIV vaccine$137,160
K23 · FY2009 · AI · contact PI